Ardelyx vs Sinovac Biotech
Ardelyx reported revenue of $407 million in fiscal 2025, about the same as Sinovac Biotech's $386 million in fiscal 2025. Ardelyx's revenue grew 22.1% in its latest year, and Sinovac Biotech's grew 6.8%. Ardelyx had an operating margin of -10.1%, against -127.0% at Sinovac Biotech. Free cash flow was −$44 million at Ardelyx and −$561 million at Sinovac Biotech.
Side by side
| Ardelyx | Sinovac Biotech | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $407M | $386M |
| Revenue growth | 22.1% | 6.8% |
| Revenue growth a year, last 5 years | 121.7% | −5.4% |
| Gross margin | 90.3% | 67.9% |
| Operating margin | −10.1% | −127.0% |
| Net margin | −15.1% | −51.5% |
| Free cash flow | −$44M | −$561M |
| Free cash flow margin | −10.8% | −145.4% |
| Return on capital | −36.1% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $3.5B |
| Change in diluted share count | 2.5% | 0.0% |
| Last close | $3.06 | — |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.9 million, sold $4.3 million | — |
| Piotroski F-score | 2 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ArdelyxSinovac Biotech
Operating margin
Percent of revenue
ArdelyxSinovac Biotech
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArdelyxSinovac Biotech
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ardelyx and Sinovac Biotech pages.